Germantown, Maryland and Hilden, Germany, January 14th, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic test to detect latent tuberculosis (TB) infection. QFT-Plus is the fourth generation of QIAGEN’s market-leading QuantiFERON-TB technology, combining a new flexible... Read more
Notice to holders of the QIAGEN N.V. (the “Issuer”): 0.375% Senior Unsecured Convertible Notes due 2019 (the “2019 Notes”) – ISIN XS1046477235 0.875% Senior Unsecured Convertible Notes due 2021 (the “2021 Notes”) – ISIN XS1046477581 0.500% Senior Unsecured Convertible Notes due 2023 (the “2023 Notes”) – ISIN XS1682511818 1.000% Senior Unsecured Convertible Notes due 2024... Read more
Redwood City, California, and Hilden, Germany, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One will enable QIAGEN to... Read more
Hilden, Germany, and Germantown, Maryland, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to develop a proprietary new version of a QuantiFERON®-based tuberculosis (TB) test dedicated and tailored to the needs of low-resource regions with a high disease burden of TB. The new testing solution, QuantiFERON®-TB Access (QFT®... Read more
Hilden, Germany, and Germantown, Maryland, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAcube Connect, which marks the next generation of QIAGEN’s widely used QIAcube instrument and is designed to bring the benefits of automated sample processing solution to a new level. QIAcube Connect offers greatly enhanced... Read more
Hilden, Germany, and Germantown, Maryland, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the development of a range of next-generation systems for digital polymerase chain reaction (digital PCR or dPCR), one of the fastest-growing molecular testing applications in the life sciences industry. QIAGEN expects to launch a fully integrated... Read more
DEC 19 2018 QIAGEN N.V. announces that it will initiate the repurchase of a third tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between December 19, 2018 until March 8, 2019, at the latest, a third tranche of up... Read more
Suzhou, China and Cambridge, UK, December 6: Abcam plc, a global innovator in life science reagents and tools, and QIAGEN (Suzhou) Translational Medicine Co., Ltd. (QIAGEN (Suzhou)) have signed a Memorandum of Understanding (MoU) agreement to jointly develop a pipeline of Companion Diagnostic (CDx) and In Vitro Diagnostic reagents and kits, to meet the specific needs... Read more
Germantown, Maryland, and Hilden, Germany, December 6, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that a clinical development program is underway with Novartis to bring to market a molecular test as a companion diagnostic to guide the use of the investigational compound BYL719 (alpelisib) in combination with fulvestrant for men... Read more
Hilden, Germany, Germantown, Maryland, Fort Myers, Florida, November 30, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients. The partnership between QIAGEN and NeoGenomics, a leading provider of... Read more